Kawasaki, Japan

Satoshi Yanagihara

This inventor holds 2 USPTO granted patents. Top assignees: Salo Pharmaceutical Co., Ltd., Sato Pharmaceutical Co., Ltd.. Active years: 2003-2007.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Satoshi Yanagihara. Retrieved from https://idiyas.com/inventor/satoshi-yanagihara

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 9.0

ph-index = 2

Forward Citations = 22(Granted Patents)


Company Filing History:


Years Active: 2003-2007

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Satoshi Yanagihara: Innovator in Antibacterial Agents

Introduction

Satoshi Yanagihara is a notable inventor based in Kawasaki, Japan. He has made significant contributions to the field of antibacterial agents, holding a total of 2 patents. His work focuses on developing compounds that exhibit strong antibacterial properties.

Latest Patents

Yanagihara's latest patents include a 4-oxoquinolizine antibacterial agent that features a 2-pyridone skeleton as a partial structure. This invention provides a compound that demonstrates a strong antibacterial effect on gram-positive bacteria, gram-negative bacteria, and anaerobic bacteria. The compound is represented by a specific formula, which includes pharmaceutically acceptable salts.

Career Highlights

Throughout his career, Satoshi Yanagihara has worked with reputable companies such as Sato Pharmaceutical Co., Ltd. and Salo Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in the development of innovative antibacterial solutions.

Collaborations

Yanagihara has collaborated with notable coworkers, including Ryoichi Fukumoto and Hiroyuki Kusakabe. These partnerships have likely enhanced his research and development efforts in the field of pharmaceuticals.

Conclusion

Satoshi Yanagihara is a distinguished inventor whose work in antibacterial agents has the potential to impact public health significantly. His innovative approaches and collaborations continue to drive advancements in the pharmaceutical industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…